English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Cardiologia CROATICA Objectives: To compare the efficacy of ramipril and losartan in prevention of the left ventricular systolic dysfunction and heart failure in ST-elevation myocardial infarction (STEMI) patients treated by primary percutaneous coronary intervention (PPCI) in short (8 weeks) and long-term (six months) after acute coronary event. Patients and Methods: 55 STEMI patients (mean age 58.4 ±9.9 years, 63.6% of men) in Killip classes I-II were included; excluded were the patients with pulmonary edema, cardiogenic shock, brochospasm. All the patients underwent PPCI. 29 patients were randomly assigned to receive ramipril and 26 to losartan 24 to 48 hours after PPCI. Systolic function was estimated by echocardiography prior to randomization, 8 weeks and 6 months thereafter. Ejection fraction (EF) was measured by modified biplane Simpson’s method (normal levels >55%), left ventricular end-diastolic diameter (LVDD) in standard echocardiographic positions (normal levels 50 mm in 43.6% and NT-proBNP >200 pmol/l in 47.2% of patients. We did not demonstrate any significant differences between ramipril and losartan group neither at baseline nor after 8 weeks and six months of treatment in mean EF, LVDD and NT-proBNP. Within ramipril group as well as within losartan group there was an insignificant increase in mean EF and LVDD after 8 weeks and six months regarding baseline. Within the groups there was a significant decrease in mean NT-proBNP. Within ramipril group, the mean NT-proBNP decreased significantly after 8 weeks (205±180.8 pmol/l vs 67.0±66.9 pmol/l, p 200 pmol/l. The efficacy of losartan was equal to ramipril in reducing NT-proBNP and increasing EF 8 weeks and six months after randomization suggesting that they equally prevent heart failure and systolic dysfunction in STEMI patients, treated by PPCI.

cardiologia croatica

Ramipril and losartan are equal in preventing left ventricular systolic dysfunction in ST-elevation myocardial infarction patients treated by primary percutaneous coronary intervention